Australian Blood Test Targets Endometriosis Diagnosis
A new diagnostic tool identifying blood biomarkers aims to reduce the long wait times currently associated with endometriosis.
Updated on Oct. 27, 2026 in Women’s Health
Live Poll
Do you believe new diagnostic blood tests will make managing chronic health conditions easier for you?
Proteomics International Laboratories has validated a new blood test designed to detect endometriosis through 10 specific biomarkers. This development seeks to provide clinicians with a more accessible assessment tool for the condition, which currently affects 1 in 7 Australian women.
Why it matters
The test aims to bridge the significant diagnostic gap for patients, who currently face an average wait time of six to eight years for a diagnosis. By offering a blood-based alternative to the traditional gold-standard laparoscopy, the diagnostic process could become more efficient and less invasive.
The validation process involved testing 400 samples from Oxford University to identify 10 distinct blood biomarkers. The test demonstrated 90 percent sensitivity for stage four endometriosis and 68 percent sensitivity when all stages are combined.
The players
Proteomics International Laboratories
A Perth-based medical technology company that focuses on the development of predictive diagnostic tests.
Royal Women's Hospital
A Melbourne-based healthcare institution that partners on research initiatives related to women's health.
The details
Developed in Perth, the Promarker Endo test is intended to support clinicians in the management and assessment of suspected cases. The new tool holds the potential to reduce the reliance on laparoscopies, which currently serve as the definitive procedure for diagnosing the disease.
Timeline
2024: Melissa Mullan is diagnosed with stage four endometriosis.
December 2024: Visanne is added to the Pharmaceutical Benefits Scheme.
March 2025: Ryeqo is added to the Pharmaceutical Benefits Scheme.
2027: The Promarker Endo test is expected to become available in Australia.
Health Landscape
This development aligns with recent efforts to expand endometriosis care, following the inclusion of treatments like Visanne and Ryeqo in the Pharmaceutical Benefits Scheme. The test represents a shift toward earlier, non-invasive detection compared to the traditional reliance on surgical laparoscopies.
Patients may eventually benefit from a significantly shorter diagnostic journey, potentially avoiding the invasive laparoscopy required under current clinical standards. This shift could change daily health management routines by allowing for earlier interventions for those affected by the condition.
The takeaway
The test offers a promising step toward addressing the long-standing diagnostic delays that impact millions of Australian women. For those currently managing symptoms, the prospect of an earlier, blood-based diagnosis provides a potential alternative to more intensive surgical assessments.
Further reading
Learn more about advancements in clinical care on the Women’s Health section.
Source note: This article includes information reported by The West Australian.
Live Poll
Do you believe new diagnostic blood tests will make managing chronic health conditions easier for you?
